SpaceX Updates Starlink Privacy Policy to Allow AI Training as xAI Merger Talks and IPO Loom 
Sam Altman Reaffirms OpenAI’s Long-Term Commitment to NVIDIA Amid Chip Report 
Panama Supreme Court Voids CK Hutchison Port Concessions, Raising Geopolitical and Trade Concerns 
Bob Iger Plans Early Exit as Disney Board Prepares CEO Succession Vote 
Elon Musk’s Empire: SpaceX, Tesla, and xAI Merger Talks Spark Investor Debate 
SpaceX Seeks FCC Approval for Massive Solar-Powered Satellite Network to Support AI Data Centers 
Boeing Secures New Labor Contract With Former Spirit AeroSystems Employees 
Federal Judge Signals Possible Dismissal of xAI Lawsuit Against OpenAI 
Oracle Plans $45–$50 Billion Funding Push in 2026 to Expand Cloud and AI Infrastructure 
Palantir Stock Jumps After Strong Q4 Earnings Beat and Upbeat 2026 Revenue Forecast 
Nvidia Confirms Major OpenAI Investment Amid AI Funding Race 
SoftBank and Intel Partner to Develop Next-Generation Memory Chips for AI Data Centers 
Trump Threatens Aircraft Tariffs as U.S.-Canada Jet Certification Dispute Escalates 
Using the Economic Calendar to Reduce Surprise Driven Losses in Forex 
Google Cloud and Liberty Global Forge Strategic AI Partnership to Transform European Telecom Services 
WALTHAM, Mass., May 31, 2017 -- AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) today announced that company management will participate in the following investor conferences:
- Jefferies 2017 Global Healthcare Conference
Tuesday, June 6, 2017 at 9:30 a.m. ET
Location: New York, NY
- Goldman Sachs Leveraged Finance Conference
Tuesday, June 20, 2017 at 11:20 a.m. PT (2:20 p.m. ET)
Location: Palos Verdes, CA
To access the live webcasts, please visit the Investors section of the company’s website at www.amagpharma.com. A replay of each event will be archived on the site for 30 days.
About AMAG
AMAG is a biopharmaceutical company focused on developing and delivering important therapeutics, conducting clinical research in areas of unmet need and creating education and support programs for the patients and families we serve. Our currently marketed products support the health of patients in the areas of maternal and women’s health, anemia management and cancer supportive care. Through CBR®, we also help families to preserve newborn stem cells, which are used today in transplant medicine for certain cancers and blood, immune and metabolic disorders, and have the potential to play a valuable role in the ongoing development of regenerative medicine. For additional company information, please visit www.amagpharma.com.
AMAG Pharmaceuticals® is a registered trademark of AMAG Pharmaceuticals, Inc. and CBR® is a registered trademark of CBR Systems, Inc.
AMAG Pharmaceuticals Contact: Christi Waarich Associate Director, Investor Relations 617-498-7638
